Development Msl
•Download as PPT, PDF•
6 likes•1,288 views
The document discusses the evolution of medical science liaison (MSL) teams from the 1980s to present day. It describes how MSL teams initially focused on post-marketing activities but now also contribute value to clinical drug development processes like trial design and identification of new indications. The document provides examples of how MSL teams have helped pharmaceutical companies gain regulatory approval faster, lower development costs, and increase drug revenues.
Report
Share
Report
Share
![[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Highlights From 7th Medical Science Liaison/MSL Conference
Current trends, issues and challenges facing MSL's in the pharmaceutical industry. Presented at the 7th MSL Best Practices conference, April, 2010. For further information, please visit www.exlpharma.com
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...
This report provides benchmarks and metrics for medical science liaison (MSL) teams at pharmaceutical and medical device companies. It examines MSL activities in areas like thought leader management, supporting medical/clinical teams, education, and performance measurement. The report is based on surveys of over 30 companies and contains over 160 charts and tables analyzing MSL metrics across different company sizes and regions. It aims to help companies improve coordination of MSL activities and demonstrate their value.
Highlights from ExL Pharma's 6th MSL Best Practices
This document summarizes key points from ExLPharma's 6th annual MSL Best Practices conference. It discusses the evolving role of medical science liaisons (MSLs) and how they can effectively educate healthcare providers while minimizing compliance risks. The role of MSLs is varied by company but generally involves building scientific relationships with key opinion leaders. The document provides guidance on developing standard operating procedures for MSLs, clarifying their reporting structure, compensation practices, involvement in clinical trials and interactions with sales representatives to reduce promotional concerns. It emphasizes the need for MSL training, oversight and auditing to ensure their activities remain focused on non-promotional scientific exchange.
Medical Science Liaison-Aligning The Activities And Goals Of Medical Science ...
Medical Science Liaison-Aligning The Activities And Goals Of Medical Science ...Medical Science Liaison Society
Aligning the Activities and Goals of Field Based Teams for
Strengthened Corporate Sustainability
• Examining the disconnect between field based medical and corporate initiatives
• Acquiring and synthesizing field insights to drive clinical and corporate decision-making
• Demonstrating value of the expensive MSL and Advisor roles to the company
The Medical Science Liaison role is growing and being utilized in a number of various ways by different companies. This presentation discussed how they are being utilized.9th Medical Science Liaison Best Practices
This document advertises the 9th MSL Best Practices conference organized by ExL Pharma. The two-day conference on September 26-27, 2011 in San Diego will provide MSLs (medical science liaisons) with the latest information and best practices for enhancing their impact and the value they bring to pharmaceutical companies. Featured sessions will address topics like collaborating with medical affairs teams, demonstrating value through metrics, managing thought leader interactions, and future trends for the MSL role. The conference is designed for MSLs and other professionals involved in medical, scientific and clinical areas.
MSL Services Excellence: Generating Value for Diverse Customer Groups
This primary research identifies valuable insights into MSL services structure as well as the roles and responsibilities of these services. The study offers powerful insights that you will be able to use in the organization and deployment of your MSLs. Additionally, the new report will provide information on how the roles of MSLs are evolving in the changing pharmaceutical environment and how regulatory concerns are affecting the MSL landscape.
MSLs of Tomorrow: Competencies, Collaborations, and Customers
The document discusses how the roles and competencies of Medical Science Liaisons (MSLs) are changing due to shifts in the healthcare and life sciences industries. It outlines several emerging areas: MSLs may need to engage with new customer types like mid-level providers and quality managers; develop skills in business acumen, leadership without authority, and emotional intelligence; and expand their therapeutic knowledge to complex multidisciplinary areas involving devices, diagnostics, and engineering. Overall, MSLs must adapt strategically to remain valuable contributors in the changing healthcare landscape.
Roles, Resources, and Managemet of Medical Science Liaisons
This document summarizes the findings of a benchmarking report on roles, resourcing, and management of medical science liaisons (MSLs). Key findings include determining the optimal number of MSLs based on factors like product lifecycle, market monitoring, and relationship management standards. The report also examines budget allocation, value measurement, and shifting MSL responsibilities in response to changing industry dynamics. Insights are drawn from interviews with leaders from over 20 pharmaceutical companies.
Recommended
Highlights From 7th Medical Science Liaison/MSL Conference
Current trends, issues and challenges facing MSL's in the pharmaceutical industry. Presented at the 7th MSL Best Practices conference, April, 2010. For further information, please visit www.exlpharma.com
Msl activities-and-performance-measurement-cutting-edge-information-ph178-bro...
This report provides benchmarks and metrics for medical science liaison (MSL) teams at pharmaceutical and medical device companies. It examines MSL activities in areas like thought leader management, supporting medical/clinical teams, education, and performance measurement. The report is based on surveys of over 30 companies and contains over 160 charts and tables analyzing MSL metrics across different company sizes and regions. It aims to help companies improve coordination of MSL activities and demonstrate their value.
Highlights from ExL Pharma's 6th MSL Best Practices
This document summarizes key points from ExLPharma's 6th annual MSL Best Practices conference. It discusses the evolving role of medical science liaisons (MSLs) and how they can effectively educate healthcare providers while minimizing compliance risks. The role of MSLs is varied by company but generally involves building scientific relationships with key opinion leaders. The document provides guidance on developing standard operating procedures for MSLs, clarifying their reporting structure, compensation practices, involvement in clinical trials and interactions with sales representatives to reduce promotional concerns. It emphasizes the need for MSL training, oversight and auditing to ensure their activities remain focused on non-promotional scientific exchange.
Medical Science Liaison-Aligning The Activities And Goals Of Medical Science ...
Medical Science Liaison-Aligning The Activities And Goals Of Medical Science ...Medical Science Liaison Society
Aligning the Activities and Goals of Field Based Teams for
Strengthened Corporate Sustainability
• Examining the disconnect between field based medical and corporate initiatives
• Acquiring and synthesizing field insights to drive clinical and corporate decision-making
• Demonstrating value of the expensive MSL and Advisor roles to the company
The Medical Science Liaison role is growing and being utilized in a number of various ways by different companies. This presentation discussed how they are being utilized.9th Medical Science Liaison Best Practices
This document advertises the 9th MSL Best Practices conference organized by ExL Pharma. The two-day conference on September 26-27, 2011 in San Diego will provide MSLs (medical science liaisons) with the latest information and best practices for enhancing their impact and the value they bring to pharmaceutical companies. Featured sessions will address topics like collaborating with medical affairs teams, demonstrating value through metrics, managing thought leader interactions, and future trends for the MSL role. The conference is designed for MSLs and other professionals involved in medical, scientific and clinical areas.
MSL Services Excellence: Generating Value for Diverse Customer Groups
This primary research identifies valuable insights into MSL services structure as well as the roles and responsibilities of these services. The study offers powerful insights that you will be able to use in the organization and deployment of your MSLs. Additionally, the new report will provide information on how the roles of MSLs are evolving in the changing pharmaceutical environment and how regulatory concerns are affecting the MSL landscape.
MSLs of Tomorrow: Competencies, Collaborations, and Customers
The document discusses how the roles and competencies of Medical Science Liaisons (MSLs) are changing due to shifts in the healthcare and life sciences industries. It outlines several emerging areas: MSLs may need to engage with new customer types like mid-level providers and quality managers; develop skills in business acumen, leadership without authority, and emotional intelligence; and expand their therapeutic knowledge to complex multidisciplinary areas involving devices, diagnostics, and engineering. Overall, MSLs must adapt strategically to remain valuable contributors in the changing healthcare landscape.
Roles, Resources, and Managemet of Medical Science Liaisons
This document summarizes the findings of a benchmarking report on roles, resourcing, and management of medical science liaisons (MSLs). Key findings include determining the optimal number of MSLs based on factors like product lifecycle, market monitoring, and relationship management standards. The report also examines budget allocation, value measurement, and shifting MSL responsibilities in response to changing industry dynamics. Insights are drawn from interviews with leaders from over 20 pharmaceutical companies.
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...
The Medical Affairs function plays an important role in health outcomes (HO) information exchange between bio-pharmaceutical organizations and key external stakeholders.
Development of robust health outcomes capabilities within Medical Affairs function requires an increase in the function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data as per stakeholders’ needs, and building real world data capabilities to generate and utilize health outcomes information.
This benchmarking research from Best Practices, LLC is designed to assist companies focused on oncology therapies find better ways to develop effective health outcomes groups. It provides current data and best practices from Medical Affairs leaders with an oncology focus at leading bio-pharmaceutical companies.
Download Full Report: http://bit.ly/2e3sl9Q
KOL Relationship Management in Pharma
This 3 sentence summary provides the high level and essential information from the document:
The document discusses how pharmaceutical companies can develop effective key opinion leader (KOL) relationship management (KRM) strategies and plans. It explains that while customer relationship management (CRM) focuses on immediate prescription generation, KRM aims to create long-term brand perception and influence among target audiences through KOL activities. The document also outlines some of the key elements that should be included in a robust KRM strategy and plan, such as KOL identification, customized engagement programs, and impact measurement.
Medical & Scientific Affairs (M & SA)
Medical & Scientific Affairs (M & SA) is a critical piece in the puzzle of building a GOOD to GREAT Healthcare Organization!
Medical Affairs Leadership Summit, Key APAC Insights - August 2016
1) The document summarizes insights from a medical affairs leadership summit in Asia Pacific that discussed defining medical affairs visions and missions, transforming field medical teams, the role of medical affairs in late-stage development and launch readiness.
2) Key topics included adapting medical affairs visions to evolving healthcare landscapes, enhancing field teams' business skills and ability to generate insights, challenges generating real-world evidence in diverse Asia Pacific markets, and ensuring adequate planning and resources for medical affairs involvement in launches.
3) Attendees discussed how medical affairs can demonstrate greater strategic value by engaging more stakeholders, generating regional insights, and involving earlier in product development and launches.
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
Benchmarking the Pharma Industry’s Medical Affairs Functions
Medical Affairs, as a function, sits at a crossroads in the pharmaceutical industry. The department is expected to act as a bridge between the commercial and scientific arms of an organization. Medical Affairs is further tasked with being the conduit of information between the company and external stakeholders, bringing efficacy and safety data to the medical community as well as gathering insights from the medical community to share internally. All responsibilities must be undertaken while keeping in mind strict regulatory controls and ensuring that medical data are interpreted appropriately.
ISR has designed this report to be used as a benchmarking tool for companies to compare their Medical Affairs functions to those of Top 50 pharmaceutical organizations.
See more: http://bit.ly/medaffairs
Key Opinion Leader Compensation and KOL and Medical Science Liaison Interactions
Key Opinion Leader Compensation and KOL and Medical Science Liaison InteractionsMedical Science Liaison Society
The document summarizes compensation rates for various types of thought leaders and medical professionals providing consulting services to pharmaceutical companies in Europe. It provides average hourly and flat fee ranges for different activities like speaking, advisory panels, and authorships. It also breaks down rates by company size, therapeutic area, and type of thought leader, such as their professional role and specialty. The document was presented by Dr. Samuel Dyer, the CEO and founder of a company that collects data on compensation for medical science liaisons and thought leaders.KOL MANAGEMENT
The document discusses key opinion leader (KOL) identification and selection for pharmaceutical companies. It outlines regulatory guidance requiring transparency in KOL relationships and selection criteria based on medical expertise. The document proposes that citation analysis is an effective method for determining a scientist's influence and peer esteem, as shown by Thomson Reuters' success in predicting Nobel Prize winners based primarily on citations. It provides methods for identifying KOLs based on a company's business needs, such as publication count for new markets or citation analysis for established markets. The document recommends aligning KOLs with development stages, using both established leaders and rising stars.
Medical affairs department for small organization
The document summarizes the drug development process and the role of medical affairs departments within pharmaceutical companies. It discusses the various phases of clinical drug trials from phase I to phase IV. It then outlines the structure and responsibilities of medical affairs, including clinical research, pharmacovigilance, medical information services, statistics management, and providing medical support to marketing and sales teams. A key part of medical affairs is the medical science liaison program which aims to educate medical professionals and support clinical trial recruitment through relationship building.
Trends in Medical Affairs
From Social Media through to Artificial intelligence...and more. In this presentation I covered the trends that we're currently seeing in Medical Affairs - those trends which are important now, those trends which will impact Medical Affairs in the future, and the skills required to be successful.
To read the LinkedIn article here’s the link: https://www.linkedin.com/pulse/trends-medical-affairs-presented-appa-march-14-2018-glenn-carter/
For further discussion phone us on:
Sydney (02) 8877 8777
Melbourne (03) 9938 7100
Or for additional insights go to one of our specialised websites:
Healthcare Professionals Group
(https://www.hpgconnect.com/)
Health & Aged Care Professionals (https://www.hacpconnect.com/)
Pharmaceutical & Medical Professionals
(https://www.pmpconnect.com/)
Rural & Remote Healthcare Professionals
(https://www.rrhpconnect.com/)
Coaching Action Plan for MSL - Investigator Initiated Trials
This document outlines a coaching process for an MSL (Medical Science Liaison) to help a physician develop an investigator-initiated trial. The MSL would clarify goals with the physician, determine internal and external obstacles, assess required skills, and create an action plan with short and long-term goals. The plan involves multiple meetings over 10 weeks to draft the proposal, address obstacles, develop needed skills, and finalize the proposal to align with both the physician and company's goals. The ultimate measurement of success would be company approval of the investigator-initiated trial.
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
The Update to the wildly popular Medical Affairs Resources, Structures, and Trends research from 2009 is ready! Contains linear data and new segmentation for emerging markets.
Charged with building and maintaining physician relationships, pharmaceutical Medical Affairs organizations typically oversee several important functions -- including publications, KOL programs, grants and medical education (CME) -- that have been impacted in recent years by a call for increased transparency. As such, forward-looking biopharmaceutical executives are beginning to evaluate Medical Affairs operations to ensure that the vital organization is appropriately structured and resourced to operate effectively in the current environment.
This Best Practices, LLC study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function.
The report is based on the insights of 68 Medical Affairs executives and managers at 50 leading global companies. The benchmark class in this study consists of a Mature Markets and Emerging Markets Segment. The Mature Market Segment includes 41 participants from pharma and 12 device respondents. The Emerging Markets Segment consists of 15 participants working in India, China, Brazil, and Turkey.
Strategic Medical Affairs in pharma and medical devices
Strategic medical affairs in pharma and medical devices outlines key drivers influencing the growing role of medical affairs functions. Regulatory requirements, demand for local excellence, and the need for transparency are pushing medical activities to expand in areas like medical strategy, clinical operations, and regulatory submissions. Medical affairs contributes throughout the product lifecycle by collecting and disseminating knowledge to internal and external audiences, and can help integrate products into healthcare systems from drug development to reimbursement.
Medical Affairs Resources, Structures, & Trends Report Summary
This survey summarizes research on resources, structures, and trends in medical affairs organizations. The survey collected data from 26 medical affairs leaders at 25 pharmaceutical companies. Key findings include that medical affairs groups typically have a centralized structure reporting to executives, focus over a third of their budget on clinical operations, and have experienced few decreases in resources despite some companies citing economic or product reasons. The research was conducted by Best Practices, LLC to benchmark medical affairs organizations.
Medical Affairs Resources, Structures, and Trends Report Summary
Research summary for "Medical Affairs Resources, Structures, and Trends." Contact me to view the full report.
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...
Pharmaceutical advisory boards provide strategic inputs and guidance to organizations on various business aspects. However, successful advisory board management requires optimum investment in resources and operations. To maximize the return on investment it is important for pharmaceutical and medical device professionals to ensure that the quality of meetings and dialogue with advisory boards is excellent.
This research from Best Practices, LLC is designed for pharmaceutical and biotech executives seeking ways to best utilize the knowledge of advisory boards. Research findings provide benchmarks on the appropriate structure for various types of advisory boards, selection of advisory board participants, advisory board operational and resource benchmarks.
New Health Report 2011 Il
The document discusses perceptions of value in healthcare among various stakeholders. It finds that stakeholders define value differently, with biopharma being the only group where a majority includes outcomes in their definition. Nearly a third of patients cannot define value. When given choices, stakeholders consistently ranked patient outcomes and safety as most important in determining the value of prescription medications. While most agree medications improve health, managed care executives were least convinced that the money patients spend is worth it.
Hospitals Care Systems Of Future
The document discusses the forces driving transformation in healthcare delivery over the next decade, including changing demographics, cost pressures, and payment reforms. It outlines 10 must-do strategies for hospitals to successfully transition to new payment models focused on quality and value, such as aligning with providers, improving efficiency, and developing integrated systems. Hospitals are encouraged to measure their progress in implementing the strategies using "second-curve metrics" that assess outcomes rather than volume. The strategies will help hospitals develop core competencies critical for success in the future, such as effective leadership, strategic planning, and use of data for performance improvement.
Two Heads
R&D presidents face the challenge of balancing both scientific and operational responsibilities. However, it is difficult for one person to effectively manage both roles. The document proposes appointing a Chief Operating Officer (COO) of R&D to allow the R&D president to focus solely on scientific matters while the COO handles operational issues like managing external partnerships, improving processes, and overseeing support functions. This division of roles has been successfully implemented in other industries and could help R&D organizations run more efficiently and improve performance.
How to build a "better top team"
There are three crucial steps for building an effective top executive team:
1. Get the right people on the team and remove those who are not contributing or resisting collaboration. A new CEO removed two regional executives resisting change and improved customer satisfaction ratings.
2. Ensure the top team focuses only on work that requires collective effort, like setting cross-functional priorities. Rationalizing priorities allowed one team to boost employee satisfaction from 52% to 81% in a year.
3. Address team dynamics like a lack of trust or conflicting agendas. Diagnosing issues through surveys and having the CEO intervene to broker decisions can improve collaboration, strategy alignment, and financial outcomes. Regular check-ins with lower levels also helped embed changes
5 powerful ideas on KOL network management
Many pharmaceutical companies still prefer to deal with their stakeholders one-by-one in a controlled way. They are often at their most comfortable dealing with clinical opinion leaders, talking about the benefits of their products. But are they missing a trick?
The Medical Science Liaison (MSL) & Social Networking
This document discusses using social networking for hiring, internal collaboration, and customer engagement by medical science liaisons (MSLs). It provides tips for using LinkedIn for recruiting and hiring. It also recommends using social business software like Yammer or Jive to facilitate internal collaboration for non-co-located teams. Finally, it argues that MSLs can engage thought leaders through their presence on networks like LinkedIn, QuantiaMD, and Doximity, as over 30% of thought leaders may already be on such networks. An example virtual community set up by a pharmaceutical company found KOLs had a positive response, though the sample size was small.
More Related Content
What's hot
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...
The Medical Affairs function plays an important role in health outcomes (HO) information exchange between bio-pharmaceutical organizations and key external stakeholders.
Development of robust health outcomes capabilities within Medical Affairs function requires an increase in the function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data as per stakeholders’ needs, and building real world data capabilities to generate and utilize health outcomes information.
This benchmarking research from Best Practices, LLC is designed to assist companies focused on oncology therapies find better ways to develop effective health outcomes groups. It provides current data and best practices from Medical Affairs leaders with an oncology focus at leading bio-pharmaceutical companies.
Download Full Report: http://bit.ly/2e3sl9Q
KOL Relationship Management in Pharma
This 3 sentence summary provides the high level and essential information from the document:
The document discusses how pharmaceutical companies can develop effective key opinion leader (KOL) relationship management (KRM) strategies and plans. It explains that while customer relationship management (CRM) focuses on immediate prescription generation, KRM aims to create long-term brand perception and influence among target audiences through KOL activities. The document also outlines some of the key elements that should be included in a robust KRM strategy and plan, such as KOL identification, customized engagement programs, and impact measurement.
Medical & Scientific Affairs (M & SA)
Medical & Scientific Affairs (M & SA) is a critical piece in the puzzle of building a GOOD to GREAT Healthcare Organization!
Medical Affairs Leadership Summit, Key APAC Insights - August 2016
1) The document summarizes insights from a medical affairs leadership summit in Asia Pacific that discussed defining medical affairs visions and missions, transforming field medical teams, the role of medical affairs in late-stage development and launch readiness.
2) Key topics included adapting medical affairs visions to evolving healthcare landscapes, enhancing field teams' business skills and ability to generate insights, challenges generating real-world evidence in diverse Asia Pacific markets, and ensuring adequate planning and resources for medical affairs involvement in launches.
3) Attendees discussed how medical affairs can demonstrate greater strategic value by engaging more stakeholders, generating regional insights, and involving earlier in product development and launches.
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
Benchmarking the Pharma Industry’s Medical Affairs Functions
Medical Affairs, as a function, sits at a crossroads in the pharmaceutical industry. The department is expected to act as a bridge between the commercial and scientific arms of an organization. Medical Affairs is further tasked with being the conduit of information between the company and external stakeholders, bringing efficacy and safety data to the medical community as well as gathering insights from the medical community to share internally. All responsibilities must be undertaken while keeping in mind strict regulatory controls and ensuring that medical data are interpreted appropriately.
ISR has designed this report to be used as a benchmarking tool for companies to compare their Medical Affairs functions to those of Top 50 pharmaceutical organizations.
See more: http://bit.ly/medaffairs
Key Opinion Leader Compensation and KOL and Medical Science Liaison Interactions
Key Opinion Leader Compensation and KOL and Medical Science Liaison InteractionsMedical Science Liaison Society
The document summarizes compensation rates for various types of thought leaders and medical professionals providing consulting services to pharmaceutical companies in Europe. It provides average hourly and flat fee ranges for different activities like speaking, advisory panels, and authorships. It also breaks down rates by company size, therapeutic area, and type of thought leader, such as their professional role and specialty. The document was presented by Dr. Samuel Dyer, the CEO and founder of a company that collects data on compensation for medical science liaisons and thought leaders.KOL MANAGEMENT
The document discusses key opinion leader (KOL) identification and selection for pharmaceutical companies. It outlines regulatory guidance requiring transparency in KOL relationships and selection criteria based on medical expertise. The document proposes that citation analysis is an effective method for determining a scientist's influence and peer esteem, as shown by Thomson Reuters' success in predicting Nobel Prize winners based primarily on citations. It provides methods for identifying KOLs based on a company's business needs, such as publication count for new markets or citation analysis for established markets. The document recommends aligning KOLs with development stages, using both established leaders and rising stars.
Medical affairs department for small organization
The document summarizes the drug development process and the role of medical affairs departments within pharmaceutical companies. It discusses the various phases of clinical drug trials from phase I to phase IV. It then outlines the structure and responsibilities of medical affairs, including clinical research, pharmacovigilance, medical information services, statistics management, and providing medical support to marketing and sales teams. A key part of medical affairs is the medical science liaison program which aims to educate medical professionals and support clinical trial recruitment through relationship building.
Trends in Medical Affairs
From Social Media through to Artificial intelligence...and more. In this presentation I covered the trends that we're currently seeing in Medical Affairs - those trends which are important now, those trends which will impact Medical Affairs in the future, and the skills required to be successful.
To read the LinkedIn article here’s the link: https://www.linkedin.com/pulse/trends-medical-affairs-presented-appa-march-14-2018-glenn-carter/
For further discussion phone us on:
Sydney (02) 8877 8777
Melbourne (03) 9938 7100
Or for additional insights go to one of our specialised websites:
Healthcare Professionals Group
(https://www.hpgconnect.com/)
Health & Aged Care Professionals (https://www.hacpconnect.com/)
Pharmaceutical & Medical Professionals
(https://www.pmpconnect.com/)
Rural & Remote Healthcare Professionals
(https://www.rrhpconnect.com/)
Coaching Action Plan for MSL - Investigator Initiated Trials
This document outlines a coaching process for an MSL (Medical Science Liaison) to help a physician develop an investigator-initiated trial. The MSL would clarify goals with the physician, determine internal and external obstacles, assess required skills, and create an action plan with short and long-term goals. The plan involves multiple meetings over 10 weeks to draft the proposal, address obstacles, develop needed skills, and finalize the proposal to align with both the physician and company's goals. The ultimate measurement of success would be company approval of the investigator-initiated trial.
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
The Update to the wildly popular Medical Affairs Resources, Structures, and Trends research from 2009 is ready! Contains linear data and new segmentation for emerging markets.
Charged with building and maintaining physician relationships, pharmaceutical Medical Affairs organizations typically oversee several important functions -- including publications, KOL programs, grants and medical education (CME) -- that have been impacted in recent years by a call for increased transparency. As such, forward-looking biopharmaceutical executives are beginning to evaluate Medical Affairs operations to ensure that the vital organization is appropriately structured and resourced to operate effectively in the current environment.
This Best Practices, LLC study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function.
The report is based on the insights of 68 Medical Affairs executives and managers at 50 leading global companies. The benchmark class in this study consists of a Mature Markets and Emerging Markets Segment. The Mature Market Segment includes 41 participants from pharma and 12 device respondents. The Emerging Markets Segment consists of 15 participants working in India, China, Brazil, and Turkey.
Strategic Medical Affairs in pharma and medical devices
Strategic medical affairs in pharma and medical devices outlines key drivers influencing the growing role of medical affairs functions. Regulatory requirements, demand for local excellence, and the need for transparency are pushing medical activities to expand in areas like medical strategy, clinical operations, and regulatory submissions. Medical affairs contributes throughout the product lifecycle by collecting and disseminating knowledge to internal and external audiences, and can help integrate products into healthcare systems from drug development to reimbursement.
Medical Affairs Resources, Structures, & Trends Report Summary
This survey summarizes research on resources, structures, and trends in medical affairs organizations. The survey collected data from 26 medical affairs leaders at 25 pharmaceutical companies. Key findings include that medical affairs groups typically have a centralized structure reporting to executives, focus over a third of their budget on clinical operations, and have experienced few decreases in resources despite some companies citing economic or product reasons. The research was conducted by Best Practices, LLC to benchmark medical affairs organizations.
Medical Affairs Resources, Structures, and Trends Report Summary
Research summary for "Medical Affairs Resources, Structures, and Trends." Contact me to view the full report.
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...
Pharmaceutical advisory boards provide strategic inputs and guidance to organizations on various business aspects. However, successful advisory board management requires optimum investment in resources and operations. To maximize the return on investment it is important for pharmaceutical and medical device professionals to ensure that the quality of meetings and dialogue with advisory boards is excellent.
This research from Best Practices, LLC is designed for pharmaceutical and biotech executives seeking ways to best utilize the knowledge of advisory boards. Research findings provide benchmarks on the appropriate structure for various types of advisory boards, selection of advisory board participants, advisory board operational and resource benchmarks.
New Health Report 2011 Il
The document discusses perceptions of value in healthcare among various stakeholders. It finds that stakeholders define value differently, with biopharma being the only group where a majority includes outcomes in their definition. Nearly a third of patients cannot define value. When given choices, stakeholders consistently ranked patient outcomes and safety as most important in determining the value of prescription medications. While most agree medications improve health, managed care executives were least convinced that the money patients spend is worth it.
Hospitals Care Systems Of Future
The document discusses the forces driving transformation in healthcare delivery over the next decade, including changing demographics, cost pressures, and payment reforms. It outlines 10 must-do strategies for hospitals to successfully transition to new payment models focused on quality and value, such as aligning with providers, improving efficiency, and developing integrated systems. Hospitals are encouraged to measure their progress in implementing the strategies using "second-curve metrics" that assess outcomes rather than volume. The strategies will help hospitals develop core competencies critical for success in the future, such as effective leadership, strategic planning, and use of data for performance improvement.
Two Heads
R&D presidents face the challenge of balancing both scientific and operational responsibilities. However, it is difficult for one person to effectively manage both roles. The document proposes appointing a Chief Operating Officer (COO) of R&D to allow the R&D president to focus solely on scientific matters while the COO handles operational issues like managing external partnerships, improving processes, and overseeing support functions. This division of roles has been successfully implemented in other industries and could help R&D organizations run more efficiently and improve performance.
How to build a "better top team"
There are three crucial steps for building an effective top executive team:
1. Get the right people on the team and remove those who are not contributing or resisting collaboration. A new CEO removed two regional executives resisting change and improved customer satisfaction ratings.
2. Ensure the top team focuses only on work that requires collective effort, like setting cross-functional priorities. Rationalizing priorities allowed one team to boost employee satisfaction from 52% to 81% in a year.
3. Address team dynamics like a lack of trust or conflicting agendas. Diagnosing issues through surveys and having the CEO intervene to broker decisions can improve collaboration, strategy alignment, and financial outcomes. Regular check-ins with lower levels also helped embed changes
What's hot (20)
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...
Medical Affairs Leadership Summit, Key APAC Insights - August 2016
Medical Affairs Leadership Summit, Key APAC Insights - August 2016
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...
Benchmarking the Pharma Industry’s Medical Affairs Functions
Benchmarking the Pharma Industry’s Medical Affairs Functions
Key Opinion Leader Compensation and KOL and Medical Science Liaison Interactions
Key Opinion Leader Compensation and KOL and Medical Science Liaison Interactions
Coaching Action Plan for MSL - Investigator Initiated Trials
Coaching Action Plan for MSL - Investigator Initiated Trials
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report Summary
Strategic Medical Affairs in pharma and medical devices
Strategic Medical Affairs in pharma and medical devices
Medical Affairs Resources, Structures, & Trends Report Summary
Medical Affairs Resources, Structures, & Trends Report Summary
Medical Affairs Resources, Structures, and Trends Report Summary
Medical Affairs Resources, Structures, and Trends Report Summary
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...
Viewers also liked
5 powerful ideas on KOL network management
Many pharmaceutical companies still prefer to deal with their stakeholders one-by-one in a controlled way. They are often at their most comfortable dealing with clinical opinion leaders, talking about the benefits of their products. But are they missing a trick?
The Medical Science Liaison (MSL) & Social Networking
This document discusses using social networking for hiring, internal collaboration, and customer engagement by medical science liaisons (MSLs). It provides tips for using LinkedIn for recruiting and hiring. It also recommends using social business software like Yammer or Jive to facilitate internal collaboration for non-co-located teams. Finally, it argues that MSLs can engage thought leaders through their presence on networks like LinkedIn, QuantiaMD, and Doximity, as over 30% of thought leaders may already be on such networks. An example virtual community set up by a pharmaceutical company found KOLs had a positive response, though the sample size was small.
Medical Affairs Asia Forum 2014
This document provides information about the 3rd Annual Medical Affairs Asia Summit taking place from August 26-29, 2014 in Singapore. The summit will feature over 85% new speakers and focus on advancing effective communication and collaboration with internal and external stakeholders. It will include keynote speeches, panel discussions, and workshops on topics like medical affairs strategies, stakeholder engagement, regulatory trends, and collaborating with marketing. The event is aimed at medical affairs professionals in the pharmaceutical and healthcare industries in Asia.
Optimizing KOL Relationships Report Summary
Key Opinion Leaders (KOLs) play a critical role in educating the medical and scientific communities to build awareness about the latest medical therapies and novel mechanisms of action. KOL relationship management has thus emerged as a necessary and vital part of brand success. In an effort to examine how leading pharmaceutical companies approach KOL management, this research by Best Practices, LLC identifies the key elements of KOL management excellence, from structure and strategies to MSL roles and KOL activity assessment.
Key Opinion Leader Management
Visdios is a specialist in key opinion leader management, development, implement process and also manage all kind of KOL solutions across your company. We engage with our valuable customers to get a real understanding of their business requirements.
http://visdios.com/kol-management-india/
Medical Affairs Consortium
The best Medical Affairs organizations are evolving from a support-only function to a strategic partner of the business. Explore a common set of Medical Affairs challenges with other leaders from Pharma, Biotech, and Medical Device companies.
10 essential questions for successful kol management
The document outlines 10 essential questions for successful KOL management programs. The questions cover defining KOLs, conducting targeted KOL mapping, considering KOL networks not just individuals, defining long-term KOL strategies, building collaborative approaches, dedicating teams to KOL management, using technology to optimize interactions, remunerating KOLs appropriately and transparently, measuring and evaluating KOL interactions, and sharing learnings internally. Successful KOL programs require comprehensive planning and ongoing engagement with a diverse range of stakeholders over the long term.
Viewers also liked (7)
The Medical Science Liaison (MSL) & Social Networking
The Medical Science Liaison (MSL) & Social Networking
10 essential questions for successful kol management
10 essential questions for successful kol management
Similar to Development Msl
Clinical Recruitment Planning Strategies
The document discusses the importance of early clinical recruitment planning for drug development programs. It notes that delays in recruitment can significantly increase costs and impact revenue opportunities due to later market entry. Early planning allows consideration of factors like disease characteristics, enrollment population size, competition, and protocol challenges that influence feasibility. Comprehensive recruitment programs costing 1-12% of delay costs can help avoid delays and ensure timely trial completion and drug approval.
Medical Science Liaison Webinarv 2009
The document discusses best practices for pharmaceutical companies in developing and managing relationships with key opinion leaders (KOLs) through medical science liaisons (MSLs). It provides insights from benchmarking research on the roles of MSLs at different stages of product development and lifecycles. Companies must determine MSL field force size based on factors like product lifecycle, thought leader coverage, and franchise objectives. Developing and maintaining KOL relationships is important for gathering market insights and competitive intelligence.
Best in-class Medical Science Liasons
Method, tools and recommendations to boost Medical Science Liaisons Competence and performance.
Presentation of best practices to manage key opinion leaders
Tricks of the Trade: Patient Recruitment & Retention for Different Study Types
In efforts to raise the bar for medical advancement, clinical trials are growing increasingly complex. This complexity, more often than not, leads to costly delays in enrollment. In this ebook, we'll take a look at 4 case studies for different study types, and examine the unique factors to consider during planning.
Educating KOLs, Physicians, Patients, and Payers to support successful produc...
The document discusses best practices for educating key stakeholders to support successful product launches. It finds that companies should:
1) Start thought leader engagement early, as early as pre-clinical trials, through communication, advisory boards, and developing long-term strategies.
2) Seed medical science liaisons in phase 3 trials and grow their numbers each subsequent year leading up to launch.
3) Oncology companies may be more willing to take risks with investigator-initiated trials earlier to explore new uses and populations.
Precision Medicine and Evolving Drug Development in China
This paper talks about the surge in clinical business in China Lately and the factors contributing to it.
The Integrated Early Drug Development Platform White Paper
Is it possible to deal with the explosion of complexity in the early clinical development space? Is the traditional clinical pharmacology unit obsolete? The answers are yes and no, respectively. The optimal engine for early clinical development in the modern era is an integrated early drug development platform.
Assignment Steps Resources Tutorial help on Excel® and Word fun.docx
Assignment Steps
Resources: Tutorial help on Excel® and Word functions can be found on the Microsoft® Office website. There are also additional tutorials via the web offering support for Office products.
Scenario: Imagine you are a business consultant to a firm of your choice. You have been asked to analyze, advise, and create recommendations on how the firm can ensure its future success in its current market.
Work with your instructor to choose a firm that matches the following criteria: a publicly-traded company operating in the U.S. market. Note: A publicly-traded company is a private-sector firm owned by its shareholders/stock holders.
Prepare a minimum 1,050-word analysis of economic data and business data to explain how the core economic principles impact the sustainability of the firm and what actions the firm can take to ensure success.
Address the following:
· Identify the market structure your chosen firm operates in, analyze your chosen firm's current market share, and identify the firm's local/global competitors. Analyze the barriers to entry in this market to illustrate the potential for new competition and its impact on your firm's future in the market. Hints: Be sure you review the barriers to entry discussed in the course text. You might consider presenting the data graphically.
· Identify and explain trends in current macroeconomic indicators for last three years including:
· Current stage of the business cycle.
· Real gross domestic product (GDP).
· Inflation as measured by the consumer price index (CPI).
· Unemployment rate.
· Federal funds rate.
· Current rate for borrowing funds such as the so-called "prime rate." Note: A requirement of the Week 1 Influence of Economics on Household Decision Making report was to gather data on the CPI, GDP, and interest rates, so you should consider reviewing the feedback you received on the Week 1 report.
· Evaluate trends in demand over last three years and explain their impact on the industry and the firm. Include quarterly (last two quarters) and annual sales (last three years) figures for the product your firm sells. Create business strategies by analyzing information and data related to the demand for and supply of your firm's product(s) to support your recommendation for the firm's actions. Remember to include a graphical representation of the data and information used in your analysis.
· Examine available, current data and information, such as pricing and the availability of substitutes, and explain how you could determine the price elasticity of demand for your firm's product. Assess how the price elasticity of demand impacts the firm's pricing decisions and revenue growth.
· Apply the concepts of variable and fixed costs to your firm for informing its output decisions. For instance, analyze how different kinds of costs (labor, research and development, raw materials) affect the firm's level of output.
· Based on the data gathered and analysis performed for this report write a .
Regulation reimbursement and evidence on NMT
This document discusses regulatory approval and reimbursement for new medical technologies. It notes challenges with rising costs and uncertainty of drug development. It describes expedited FDA pathways like Fast Track, Priority Review, and Breakthrough Therapy Designation. While approval and coverage don't always align, experiences with parallel FDA/CMS review and conditional approvals in Europe aim to better link evidence standards. Adaptive pathways could approve technologies for narrow uses with commitments for further study. The goal is improving development efficiency and patients' access to promising new options.
Myelin repair open science summit 07.31.10 v2
The document discusses the Myelin Repair Foundation's (MRF) mission to accelerate the discovery of treatments for multiple sclerosis (MS) by establishing a new paradigm for medical research. It outlines some of the inefficiencies of the current academic research and drug discovery system. The MRF aims to coordinate disease-specific research, protect intellectual property, and transition promising targets to clinical candidates more efficiently through its Accelerated Research Collaboration model. It summarizes the MRF's research progress and plans over its first five years and outlines strategies to further translate its discoveries.
Clinical Pharmacology: Leveraging Science to Provide Access
1) The document discusses the paradigm shift in biomarker development from a "learn and confirm" model to an "identify, confirm, refine, and learn" model to continuously learn from clinical trials.
2) It outlines policies used by the FDA to incentivize orphan drug development, including expedited programs, marketing exclusivity, and fee reductions. International collaboration is important for developing policies tailored to individual countries.
3) Successful partnerships between the FDA, NIH, patient groups, and industry have helped advance rare disease drug development, including through biospecimen repositories and training programs.
pc15147_brochure
The 3rd Annual Investigator Initiated and Sponsored Research conference will take place January 21-22, 2015 in Philadelphia, PA. The conference will provide insights from industry leaders on building standards for determining fair market value, transparency, and reporting practices for investigator initiated studies, investigator sponsored trials, and cooperative group research. Participants can choose from in-depth workshops, breakout sessions, and think tanks on optimizing global research, conducting fair market value analysis, leveraging master protocols, and developing tactics for negotiating investigator initiated study agreements. The goal is to create a platform for developing standards in these important areas of clinical research.
Disseminate Clinical Data Early to Support Payer Coverage Decisions
This document summarizes Todd Berner's presentation on early dissemination of clinical data to support payer coverage decisions. The presentation discusses comparative effectiveness research standards and how cost, comparators, and ambiguous results should be handled. It also addresses tailoring drug development to patient heterogeneity and biomarkers. Developing an open dialogue with payers throughout drug development is emphasized to demonstrate clinical and economic value. Field teams can establish relationships, disseminate outcomes data, and conduct research to support products. The goal is for clinical programs to demonstrate value through meaningful endpoints and real-world evidence.
Dr. Anoop Medical Advisor CV (2)
Dr. Anoop Hajare has over 3 years of experience in medico-marketing at Mylan Pharmaceuticals and Glenmark Pharmaceuticals. At Mylan, he helped launch several women's health products and led scientific activities including advisory panels and CME events. He provided medical support, trained field staff, and developed legal agreements. Previously at Glenmark, he supported multiple product launches and conducted various studies. Dr. Hajare aims to take on a challenging and prospective role in medico-marketing that encourages constant learning and exposure to new trends.
Solving the operational challenges of oncology clinical trials
This executive briefing explores new strategies for solving your oncology clinical operations challenges. It also features valuable insights into how you can enrich your site selection, speed up your start-up times and maximize patient recruitment opportunities here in North America.
Improving Chronic Care - a NZ experience using a breakthrough series collabor...
Improving Chronic Care - a NZ experience using a breakthrough series collabor...Health Informatics New Zealand
Dr Janine Bycroft, Gayl Humphrey, Dr Celia Palmer, Kate Healey, Dr Mazin Ghafel
Auckland DHB, Planning & Funding Team
Move Your Research Out of the Ivory Tower and Impact Health: Translating Earl...
This presentation highlights how the UCSF Clinical and Translational Science Institute (CTSI) enhances and facilitates early-stage research efforts at UCSF and UCSF/industry partnerships - to develop new treatments, diagnostics and prevention.
Do you know how many rewarding job opportunities exist in the Clinical resea...
If you are a BSc/MSc/PhD or MD/PharmD in career change, you can see some of the available career opportunities in the Clinical research industry and how to get in this field in this presentation made on Jan 14, 2017 at the Pharmacolloque 2017:
https://cra-school.com/news/
BBCR Innovation Approach
The challenges of our time require a strategic approach to build the drugs and devices of the future. Our broad knowledge and long-term experience allow us to provide our customers with Innovative solutions and risk management.
Scenario A specialty memory chip manufacturer is located in South.docx
Here are three strategic goals that align with the vision and mission statements:
1. Improve quality of care by investing in advanced medical technology and equipment. This supports the mission of providing quality services and the vision of becoming the leading healthcare provider in the region.
2. Expand patient services to include primary care, dental, behavioral health and community outreach programs. This will help achieve the mission of educating the public and the vision of growing the facility over time.
3. Develop strategic partnerships with insurance companies and government organizations to increase patient volume and ensure financial sustainability. This supports both the mission of serving the local community and the vision of a larger, more profitable facility in the long run.
Similar to Development Msl (20)
Tricks of the Trade: Patient Recruitment & Retention for Different Study Types
Tricks of the Trade: Patient Recruitment & Retention for Different Study Types
Educating KOLs, Physicians, Patients, and Payers to support successful produc...
Educating KOLs, Physicians, Patients, and Payers to support successful produc...
Precision Medicine and Evolving Drug Development in China
Precision Medicine and Evolving Drug Development in China
The Integrated Early Drug Development Platform White Paper
The Integrated Early Drug Development Platform White Paper
Assignment Steps Resources Tutorial help on Excel® and Word fun.docx
Assignment Steps Resources Tutorial help on Excel® and Word fun.docx
Clinical Pharmacology: Leveraging Science to Provide Access
Clinical Pharmacology: Leveraging Science to Provide Access
Disseminate Clinical Data Early to Support Payer Coverage Decisions
Disseminate Clinical Data Early to Support Payer Coverage Decisions
Solving the operational challenges of oncology clinical trials
Solving the operational challenges of oncology clinical trials
Improving Chronic Care - a NZ experience using a breakthrough series collabor...
Improving Chronic Care - a NZ experience using a breakthrough series collabor...
Move Your Research Out of the Ivory Tower and Impact Health: Translating Earl...
Move Your Research Out of the Ivory Tower and Impact Health: Translating Earl...
Do you know how many rewarding job opportunities exist in the Clinical resea...
Do you know how many rewarding job opportunities exist in the Clinical resea...
Scenario A specialty memory chip manufacturer is located in South.docx
Scenario A specialty memory chip manufacturer is located in South.docx
Development Msl
- 1. David Cram, Pharm.D. Associate Director, MSL Program Genentech PLEASE NOTE THAT THESE ARE MY VIEWS AND NOT NECESSARILY THOSE OF GENENTECH
- 7. 1 Million $ per Day